Investors Encouraged to Lead Class Action Against Capricor for Securities Fraud
In recent news, shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) are being reminded of a significant opportunity to lead a class action lawsuit aimed at addressing alleged securities fraud involving the company. This initiative is spearheaded by the national shareholder rights litigation firm, Schall, Brown & Schwartz LLP (SBS), which specializes in securities class action cases and shareholder rights litigation.
The lawsuit revolves around claims that Capricor made false and misleading statements related to clinical data for their drug, Deramiocel, which could lead to severe implications for the investors involved. According to the complaint, the company allegedly altered its statistical analysis plan for the clinical data related to Deramiocel. This shift occurred despite the FDA not approving these changes in the pre-specified plan prior to resubmitting their Biologics License Application (BLA). As a result, Capricor faced substantial risks regarding the FDA’s approval based on insufficient evidence of the drug's effectiveness.
During the class period, which is defined from December 17, 2025, to July 26, 2026, shareholders who acquired shares are encouraged to assess their rights and consider potential lead plaintiff appointments. It's important to note that becoming a lead plaintiff is not a prerequisite for recovering any losses.
The deadline for filing claims is set for September 28, 2026. Investors who have experienced financial losses due to their engagement with Capricor's stock during this period are strongly encouraged to participate in the lawsuit. This class action suit allows them the opportunity to seek recourse and recover perceived losses resulting from the misleading conduct of the company.
As the case progresses, it is vital for involved shareholders to contact the Schall, Brown & Schwartz LLP team directly. Investors can reach out to Brian Schall or David Schwartz at their Los Angeles office by calling 310-301-3335 for a free discussion regarding their rights.
The firm pledges to provide a dedicated advocacy platform for its clients, emphasizing its commitment to aggressively represent shareholders' interests. They have a proven track record of assisting investors globally, enabling them to navigate the complexities of securities class action lawsuits.
Investors must understand the implications of the current case as it unfolds. It's also crucial to recognize that, as of now, the class for this situation has not yet been certified, meaning that shareholders who opt not to take action will remain absent class members and miss out on any potential benefits of the lawsuit.
With allegations of misrepresentation swirling around Capricor, shareholders ought to explore their options promptly. By leveraging the legal expertise of SBS Law, shareholders can better position themselves to recover losses and ensure that their rights are upheld throughout the judicial process.
In conclusion, the recent developments concerning Capricor Therapeutics Inc. underscore the importance of transparency in corporate communication, especially within the pharmaceutical industry. Investors should monitor these proceedings closely and consider taking advantage of the legal pathways available to safeguard their financial investments.
The lawsuit revolves around claims that Capricor made false and misleading statements related to clinical data for their drug, Deramiocel, which could lead to severe implications for the investors involved. According to the complaint, the company allegedly altered its statistical analysis plan for the clinical data related to Deramiocel. This shift occurred despite the FDA not approving these changes in the pre-specified plan prior to resubmitting their Biologics License Application (BLA). As a result, Capricor faced substantial risks regarding the FDA’s approval based on insufficient evidence of the drug's effectiveness.
During the class period, which is defined from December 17, 2025, to July 26, 2026, shareholders who acquired shares are encouraged to assess their rights and consider potential lead plaintiff appointments. It's important to note that becoming a lead plaintiff is not a prerequisite for recovering any losses.
The deadline for filing claims is set for September 28, 2026. Investors who have experienced financial losses due to their engagement with Capricor's stock during this period are strongly encouraged to participate in the lawsuit. This class action suit allows them the opportunity to seek recourse and recover perceived losses resulting from the misleading conduct of the company.
As the case progresses, it is vital for involved shareholders to contact the Schall, Brown & Schwartz LLP team directly. Investors can reach out to Brian Schall or David Schwartz at their Los Angeles office by calling 310-301-3335 for a free discussion regarding their rights.
The firm pledges to provide a dedicated advocacy platform for its clients, emphasizing its commitment to aggressively represent shareholders' interests. They have a proven track record of assisting investors globally, enabling them to navigate the complexities of securities class action lawsuits.
Investors must understand the implications of the current case as it unfolds. It's also crucial to recognize that, as of now, the class for this situation has not yet been certified, meaning that shareholders who opt not to take action will remain absent class members and miss out on any potential benefits of the lawsuit.
With allegations of misrepresentation swirling around Capricor, shareholders ought to explore their options promptly. By leveraging the legal expertise of SBS Law, shareholders can better position themselves to recover losses and ensure that their rights are upheld throughout the judicial process.
In conclusion, the recent developments concerning Capricor Therapeutics Inc. underscore the importance of transparency in corporate communication, especially within the pharmaceutical industry. Investors should monitor these proceedings closely and consider taking advantage of the legal pathways available to safeguard their financial investments.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.